BET Cancer Drugs Fail Because BRD2 and BRD4 Do Different Jobs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- MPI-IE researchers led by Asifa Akhtar published a Nature Genetics study (April 2026, DOI: 10.1038/s41588-026-02533-x) finding that BET inhibitor cancer drugs have underperformed in patients because the field assumed BRD2 and BRD4 did the same job — they don't.
- BRD2 acts as a "stage manager" that assembles and organizes the molecular components needed to start transcription, while BRD4 triggers the final release of RNA Polymerase II, meaning current drugs blocking both simultaneously interfere with multiple steps of gene activation at once.
- The enzyme MOF places histone acetylation "bookmarks" on chromatin that guide BRD2 to its targets; when MOF is removed, BRD2 can no longer stay attached to chromatin, while other BET proteins remain largely unaffected.
- BRD2's clustering function is functionally essential, not decorative — first author Umut Erdogdu removed only the clustering domain and gene transcription slowed almost as much as when the entire BRD2 protein was deleted.
- The findings point future cancer drug development away from broadly blocking all BET proteins through their shared chromatin-binding feature and toward selectively targeting BRD2 or BRD4 individually, which the researchers say could yield more effective and predictable treatments.
- BET inhibitors have produced "modest benefits, notable side effects, and no reliable way to predict who might respond" in real patients, despite strong preclinical results over more than a decade of testing.
Why it matters: BET inhibitors have been tested in cancer patients for over a decade with consistently disappointing results, and the new study argues the problem may not be the drug class but the blanket approach: drugs that block BRD2 and BRD4 together produce unpredictable effects because the two proteins do different jobs. If validated, this reframes a large body of failed BET clinical trials as a targeting-design failure rather than a biology failure, and gives drug developers a concrete path — selective BRD2 or BRD4 inhibitors — to revisit a once-promising class of cancer therapy.
